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DepressionWith Atypical Features and Increase in Obesity,
BodyMass Index,Waist Circumference, and FatMass
A Prospective, Population-Based Study
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Martin Preisig, MD, MPH
IMPORTANCE Depression and obesity are 2 prevalent disorders that have been repeatedly
shown to be associated. However, the mechanisms and temporal sequence underlying this
association are poorly understood.
OBJECTIVE To determine whether the subtypes of major depressive disorder (MDD;
melancholic, atypical, combined, or unspecified) are predictive of adiposity in terms of the
incidence of obesity and changes in bodymass index (calculated as weight in kilograms
divided by height in meters squared), waist circumference, and fat mass.
DESIGN, SETTING, AND PARTICIPANTS This prospective population-based cohort study,
CoLaus (Cohorte Lausannoise)/PsyCoLaus (Psychiatric arm of the CoLaus Study), with 5.5
years of follow-up included 3054 randomly selected residents (mean age, 49.7 years; 53.1%
were women) of the city of Lausanne, Switzerland (according to the civil register), aged 35 to
66 years in 2003, who accepted the physical and psychiatric baseline and physical follow-up
evaluations.
EXPOSURES Depression subtypes according to the DSM-IV. Diagnostic criteria at baseline and
follow-up, as well as sociodemographic characteristics, lifestyle (alcohol and tobacco use and
physical activity), andmedication, were elicited using the semistructured Diagnostic
Interview for Genetic Studies.
MAIN OUTCOMES ANDMEASURES Changes in bodymass index, waist circumference, and fat
mass during the follow-up period, in percentage of the baseline value, and the incidence of
obesity during the follow-up period among nonobese participants at baseline. Weight, height,
waist circumference, and body fat (bioimpedance) were measured at baseline and follow-up
by trained field interviewers.
RESULTS Only participants with the atypical subtype of MDD at baseline revealed a higher
increase in adiposity during follow-up than participants without MDD. The associations
between this MDD subtype and bodymass index (β = 3.19; 95% CI, 1.50-4.88), incidence of
obesity (odds ratio, 3.75; 95% CI, 1.24-11.35), waist circumference in both sexes (β = 2.44;
95% CI, 0.21-4.66), and fat mass in men (β = 16.36; 95% CI, 4.81-27.92) remained significant
after adjustments for a wide range of possible cofounding.
CONCLUSIONS AND RELEVANCE The atypical subtype of MDD is a strong predictor of obesity.
This emphasizes the need to identify individuals with this subtype of MDD in both clinical and
research settings. Therapeutic measures to diminish the consequences of increased appetite
during depressive episodes with atypical features are advocated.
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M ajor depressive disorder (MDD) is among the dis-eases with the greatest public health impactworldwide1 and confers an approximately 50% el-
evated mortality of various causes.2 Obesity represents an-
othermajorburdenforpublichealthand isalsoassociatedwith
elevatedmortality.3Moreover, bothdepressionandobesityare
associatedwithvariouschronicdiseasessuchasdiabetesmelli-
tus, hypertension, dyslipidemia, cancer, and respiratory and
osteoarticular diseases.4-9 Obesity could also be one explana-
tion for the approximatelydoubled risk for cardiovascular dis-
ease (CVD)10 andcerebrovasculardiseases and theexcessmor-
tality among depressed individuals.2 Accordingly, gaining a
better understanding of the mechanisms underlying the as-
sociation betweenMDDandobesity is of high clinical and sci-
entific relevance.
Although cross-sectional studies have consistently docu-
mented a strong association between obesity and depressive
disorders or depressive symptoms,11 the direction of this as-
sociation and its underlying mechanisms are still poorly un-
derstood.Prospectivestudieshaverevealedcontradictory find-
ings regarding the sequence of onset of depression and
obesity.12,13 These inconsistent results couldbedue to the large
heterogeneity of depression as well as to methodologic vari-
ance across studies including sample selection, the length of
follow-up,andtheassessmentofdepressionandobesity.Ama-
jor limitationofpreviousprospective studies,whichalso likely
contributes to inconsistent findings, was the use of inaccu-
ratemeasures.A recent reviewofpopulation-based studieson
the prospective association between obesity and depression
could only identify 3 of 15 studies that included measured
weightandheightaswellasdirectdiagnostic interviewstoelicit
standardized criteria for depression.13 However, these 3 stud-
ies were restricted to adolescents and did not provide evi-
dence showing an association betweendepression before the
ageof 15years andobesity inyoungadulthood.Theother stud-
ies used self-reported weight and height or assessed depres-
sive symptoms using rating scales, which generally do not al-
lowcharacterization intodepression subtypes anddonot take
into account the frequent occurrence of comorbidmental dis-
orders or past psychopathology.
Because of the large heterogeneity of depression in terms
of symptommanifestations, course, and response topharma-
cologic treatment,14,15 studyingsubtypesofdepression is likely
to be amore promising approach than studying depression as
a whole with respect to cardiovascular risk. Four studies that
subdivided depression according to the presence or absence
of atypical features, suchas increasedappetite andhypersom-
niaduringdepressive episodes, showed that participantswith
these features had a higher bodymass index (BMI, calculated
as weight in kilograms divided by height in meters squared)
thanother individualswithdepressionor thosewhohadnever
been depressed.16-19 However, the cross-sectional design of 3
of these studies16,17,19 impeded drawing conclusions regard-
ing the direction of causality, whereas the population-based
prospective Zurich Cohort Study revealed a trend for a posi-
tive association between atypical depression and the average
rate ofweight gain over 20 years.18Moreover,most of the pre-
viousstudiesassessing theassociationbetweendepressionand
obesity were restricted to BMI as an adiposity measure, al-
though recent data suggest that waist circumference is more
strongly associatedwith the risk for CVD than BMI20 and that
body fat percentage could be an independent risk factor for
mortality.21
Accordingly, the aims of the present study were to assess
the prospective associations betweenMDD subtypes, includ-
ingmelancholic, atypical, combined, andunspecified, and the
subsequent changeof adiposity in termsofBMI,waist circum-
ference, and fat mass, or the incidence of obesity, in a popu-
lation-basedprospective cohortusinga standardizeddiagnos-
tic interview and anthropometric measures.
Methods
Participants
The data of the present article stemmed from CoLaus (Co-
horte Lausannoise)/PsyCoLaus (Psychiatric arm of the Co-
horte Lausannoise),22,23 cohort studies designed to prospec-
tively study mental disorders and cardiovascular risk factors
in the general population. The sample was randomly se-
lected from the residents of the city of Lausanne, Switzer-
land, in 2003, according to the civil register. Sixty-seven per-
cent of the 35- to 66-year-old participants (n = 5535) who
underwent the physical examination between 2003 and 2006
also accepted the psychiatric evaluation, which resulted in a
sample of 3719 individuals.23 Participants with a diagnosis of
bipolardisorder, schizoaffectivedisorder, schizophrenia,oreat-
ing disorders at the psychiatric baseline evaluation (n = 159)
were excluded from the present analyses because these dis-
orders are likely associatedwith changes in adiposity. Among
the remaining individuals who had undergone the psychiat-
ric baseline evaluation, 3054 also tookpart in thephysical fol-
low-upevaluation,whereas42 individualshaddiedduring the
follow-up interval and 464 were not available for the physi-
cal examination, resulting inaparticipation rateof87%among
the survivors. Themean (SD)durationof the follow-upwas5.5
(0.4) years. Comparedwith those who participated at follow-
up, nonparticipants were more likely to be men, have lower
socioeconomic status, be smokers, have ahigher alcohol con-
sumption, be less physically active, meet criteria for obesity,
and live alone at the baseline evaluation.
The institutionalethicscommitteeof theUniversityofLau-
sanne approved the CoLaus study (approvals 16/03 and 33/
09) and subsequently the PsyCoLaus study (approvals 134/05
and 239/09). All participants signed a written informed con-
sentafterhaving receivedadetaileddescriptionof thegoal and
funding of the study.
Assessments
Thephysicalmeasureswere taken in identicalwaysat thebase-
line and follow-up visits. Participants had to have fasted for
at least 8 hours and abstained from strenuous physical activ-
ity for 12hoursbefore theexamination.Weightandheightwere
measured in participants standing without shoes in light in-
door clothes. Weight was measured in kilograms to the near-
est 100 g and height wasmeasured to the nearest 5mm. Obe-
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sity was defined as a BMI of greater than or equal to 30.Waist
circumferencewasmeasuredwith anonstretchable tapeover
the unclothed abdomen at the narrowest point between the
lowest rib and the iliac crest. Two measures were made and
themean valuewas used for analyses. Fatmasswas assessed
by electrical bioelectrical bioimpedance24 using the Bodystat
1500 analyzer.
In addition, informationon sociodemographic character-
istics, current medication, and health-related behaviors, in-
cluding smoking, alcohol consumption, and physical activ-
ity, was collected through a standardized interview. White
origin was defined as having both parents and grandparents
born in a restricted list of countries (available from the au-
thors). Socioeconomic statuswas assessedusing theHollings-
head scale.25 Alcohol consumption was considered to be low
if participants drankbetween 1 and 13units perweek andhigh
if theydrank 14ormoreunits perweek. Participantswere con-
sidered physically active if they reported physical activity for
at least 20 minutes twice a week.
Diagnostic informationonmentaldisordersatbaselineand
follow-upwas collected using the French version of the semi-
structuredDiagnostic InterviewforGeneticStudies (DIGS).26,27
TheDIGSwas completedwith anxietydisorder sections of the
Schedule for Affective Disorders and Schizophrenia–Lifetime
Version.28Psychiatricdiagnoseswereassignedaccording to the
DSM-IV.29 The criteria for atypical features according to the
DSM-IV requires mood reactivity and at least 2 of the follow-
ing 4 symptoms: (1) increased appetite or significant weight
gain, (2) hypersomnia, (3) leaden paralysis, and (4) a long-
standing pattern of interpersonal rejection sensitivity. Be-
cause weight change was an outcome variable, we only ap-
plied the appetite part of the criterion, which requires either
increased appetite or weight gain. For the melancholic fea-
tures specifier, theDSM-IV requires either a loss of energy or a
lack ofmood reactivity and 3 of the following 5 symptoms: (1)
depression regularly worse in the morning, (2) early morning
awakening, (3) psychomotor retardation or agitation, (4) de-
creased appetite (we did not consider weight loss as a crite-
rion), and (5) excessive guilt. We could not take into account
the criterion “distinct quality of depressed mood” because it
was not assessed in the DIGS. Major depressive disorder was
subdividedaccording to thehistoryof atypical ormelancholic
features into 4 subtypes: (1) MDDwith atypical features only,
(2)MDDwithmelancholic featuresonly, (3)combinedMDDwith
atypicalandmelancholic featuressimultaneouslyorduringdis-
tinct episodes, and (4) unspecifiedMDDwith neither atypical
normelancholic features.For individualswhorefused theDIGS
interview at follow-up (19%),MDD status at follow-upwas as-
sessed using the Center for Epidemiologic Studies Depression
scale.A scoreof 19orhigherwas consideredan indicatorof the
presence of amajor depressive episode (MDE).30,31 Interview-
ers were required to be psychologists, who were trained over
a 2-month period. Each interview and diagnostic assignment
was reviewed by an experienced senior psychologist.
Statistical Analysis
Analyses were performed using the Statistical Analysis Sys-
temversion9.2 forWindows (SAS).AssociationsbetweenMDD
status and continuous adiposity variables (BMI,waist circum-
ference, and fat mass) were established at baseline using ro-
bust rather than multiple regression models because the re-
siduals did not reveal a normal distribution. The association
between MDD status and obesity was assessed using logistic
regression. Similar serially adjusted models were used to de-
termine the associations between depression status at base-
line and changes of continuous variables (calculated in per-
centageof thebaselinevalue)or the incidenceofobesityduring
follow-up. The choice of the covariates in themodels was de-
termined by the findings of previous studies that suggested
potential associations of these covariateswith bothMDD and
adiposity variables. The firstmodel (model 1)was adjusted for
sociodemographiccharacteristics (sex,age, socioeconomicsta-
tus, ethnicity, and living alone). The secondmodel (model 2)
was further adjusted for the effects of comorbid anxiety dis-
orders or drug dependence, treatment with antidepressants
or drugs possibly inducing weight gain (a list and the way in
which itwas extracted is provided in the eTable in the Supple-
ment) and health-related behavioral characteristics (physical
activity, alcohol consumption, and smoking status) at base-
line. The thirdmodel (model 3)was also adjusted for thepres-
ence of an MDE during the follow-up to assure that a mea-
sured association was attributable to depression status at
baseline andnot tonewepisodes that occurredduring the fol-
low-up. When the association between MDD and the inci-
dence of obesity was assessed, all models were also adjusted
for baseline BMI. We found a significant interaction between
sexanddepressionstatus toaffect thebody fatpercentage (sex
by current atypicalMDD:P = .04 andP = .006 inmodels 1 and
2, respectively).Accordingly,data regarding thisoutcomewere
analyzed separately for women andmen.
Results
Table 1provides the sampledescription for all participants ac-
cording to the MDD status. At baseline, 7.6% of the partici-
pantsmet criteria for currentMDDand36.7% reported at least
1 remittedMDE in thepast.Among theparticipantswithMDD,
approximately 10% revealed atypical and melancholic epi-
sodes (combined), 14% had atypical episodes, 29% had mel-
ancholic episodes, and48%hadunspecified episodes.Among
depressed participants taking antidepressant medication at
baseline, approximately 75% reported taking selective sero-
toninor serotonin-norepinephrine reuptake inhibitorsand less
than 10% a tricyclic or tetracyclic drug.
Themean(SD)BMIof thewholesampleatbaselinewas25.3
(4.3) (mean [SD], 24.6 [4.7] in women and 26.2 [3.7] in men).
Table 2presents thebaselineBMIof the sampleand thechange
of theBMI inpercentageduring the follow-up in functionof the
baseline depression status. Participants with current or remit-
ted atypical MDD as well as those with the current combined
MDD subtype revealed a higher BMI at baseline than individu-
als who had never been depressed. During the follow-up, the
BMI of the whole sample increased by 2.6% (SD, 6.7%). After
adjustment for sociodemographic characteristics (model 1),
participants meeting the criteria for current atypical MDD
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and, to a lesser degree, those who met criteria for remitted
atypical episodes or remitted melancholic episodes at base-
linehadahigherBMI increase thanparticipantswhohadnever
been depressed. These differences in BMI increase remained
statistically significant after additional adjustment for comor-
bidanxietyordrugdependence, lifestylecharacteristics (physi-
cal activity, alcohol consumption, and smoking) andmedica-
tionuse (antidepressantsanddrugspotentially inducingweight
gain) at baseline (model 2) and additional adjustment for the
presence of an MDE during the follow-up (model 3). In con-
trast to the participants with atypicalMDD, thosewith remit-
tedmelancholicepisodesdidnot revealahigherBMIthanthose
who had never been depressed at baseline (Table 2) or fol-
low-up (mean [SD], 26.0 [4.5] and 25.7 [4.8], respectively;
β = 0.17; 95% CI, −0.37 to 0.60).
During follow-up, the proportion of participants meet-
ing criteria for obesity increased from 12.4% to 15.5%. At
baseline, only participants with remitted atypical MDD
revealed a significantly higher prevalence of obesity than
those who had never been depressed (Table 3). Among par-
ticipants who were not obese at baseline, current atypical
MDD strongly increased the odds for being obese at the
follow-up visit regardless of the number of variables for
which the models were adjusted (Table 3). Similarly, remit-
ted melancholic MDD predicted an increased risk for obesity
after adjustment for potential confounders (models 2 and 3).
However, the prevalence of obesity in participants with
remitted melancholic MDD did not significantly differ from
that of participants who had never been depressed at base-
line (Table 3) or follow-up (mean [SD], 13.9% [1.9%] and
15.8% [0.9%], respectively; odds ratio [OR], 0.94; 95% CI,
0.66-1.33).
Themean (SD)waist circumferenceof theparticipantswas
87.6 (13.0) cm. Participants with current or remitted atypical
Table 1. Characteristics of Participants at Baseline
Characteristic
All
Participants
MDD Status
Current Remitted
No MDDAtypical Melancholic Combined Unspecified Atypical Melancholic Combined Unspecified
Total No. 3054 48 55 31 97 140 323 104 554 1702
Women, % 53.1 66.7 72.7 74.2 54.6 72.9 68.1 69.2 61.4 43.4
Age,
mean (SD), y
49.7 (8.8) 50.1 (8.0) 49.1 (8.1) 50.2 (9.2) 48.2 (7.9) 48.0 (8.9) 49.3 (8.8) 49.3 (9.2) 49.0 (8.9) 50.2 (8.8)
SES, mean (SD)a 3.4 (1.3) 2.9 (1.3) 3.1 (1.3) 2.7 (1.2) 3.3 (1.3) 3.6 (1.2) 3.4 (1.3) 3.5 (1.3) 3.5 (1.2) 3.4 (1.3)
Nonwhite, % 8.0 6.3 9.1 9.7 14.4 7.9 8.4 8.7 7.9 7.5
Living alone, % 23.2 14.6 34.5 22.6 22.7 33.6 29.4 28.8 28.3 19.1
Anxiety
disorders, %b
17.4 35.4 32.7 25.8 21.6 21.4 25.7 31.7 22.0 11.7
Smoking
status, %
Former 32.6 31.3 21.8 29.0 30.9 30.0 33.1 28.8 34.3 33.0
Current 27.3 22.9 41.8 29.0 30.9 28.6 27.2 35.6 31.8 24.6
Alcohol
intake, %c
Low 58.8 62.5 50.9 41.9 51.5 65.7 60.1 62.5 60.3 58.1
High 16.0 10.4 14.5 19.4 14.4 7.9 11.1 12.5 14.3 18.6
Substance
dependence, %d
2.5 2.1 0.0 3.2 3.1 0.7 3.7 3.8 2.9 2.2
Physically
active, %e
56.5 35.4 38.2 35.5 44.3 59.3 62.8 56.7 57.9 56.9
Antidepressant
use, %
7.5 22.9 20.0 16.1 20.6 18.6 16.7 22.1 7.4 2.2
Weight
gain–inducing
drug use, %
14.4 31.3 12.7 25.8 21.6 20.7 21.4 30.8 16.6 9.8
Age at MDD
onset, mean
(SD), y
NA 33.6
(16.7)
35.9
(13.4)
32.3
(14.0)
35.2
(13.9)
32.7
(13.1)
31.3
(12.1)
29.4
(12.2)
33.7
(12.7)
NA
Time spent in
episodes, mean
(SD), wk
NA 398.2
(524.8)
252.5
(232.2)
364.2
(516.2)
352.0
(437.9)
136.2
(207.9)
155.1
(257.8)
191.3
(364.7)
121.1
(230.7)
NA
MDE during
follow-up, %f
15.9 23.4 30.8 24.1 26.9 29.9 26.4 32.4 19.9 9.0
Abbreviations: MDD, major depressive disorder; MDE, major depressive
episode; SES, socioeconomic status.
a Hollingshead Four-Factor Index of Social Status (5 is the highest status).
bGeneralized anxiety disorder, social phobia, panic disorder, or agoraphobia.
c Number of drinks per week: low = 1-13 and high = 14 or more.
d Lifetime dependence on cocaine, heroin, stimulant, sedative, or hallucinogen.
e Physically active more than 20minutes twice a week.
f Information on 2942 participants.
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MDD had a larger waist circumference than individuals who
hadnever beendepressed (Table 4). Thewaist circumference
increasedby4.6%(8.3%)during the follow-up.Again, thepres-
ence of atypical MDD at baseline predicted elevatedwaist in-
crease during the follow-up regardless of the number of vari-
ables for which we adjusted (Table 4).
The mean (SD) fat mass percentage was 33.0% (7.9%) in
women and 22.7% (7.5%) in men at baseline. The fat mass
was higher in women with current or remitted atypical
MDD than in women who had never been depressed
(Table 5). Similarly, men with remitted atypical MDD had
an elevated fat mass at baseline. Depression status at base-
line was only predictive of the increase of body fat percent-
age in men. Men presenting with a current atypical MDD
at baseline revealed an elevated increase of body fat at
follow-up.
Table 2. BMI at Baseline and BMI Change During Follow-up by Depression Status
Depression Status
BMI at Baseline(n = 3054)
BMI Change, % of the Baseline Value
% (SD)
β (95% CI)
Mean (SD) β (95% CI)a Model 1(n = 3024)b Model 2(n = 3024)c Model 3(n = 2917)d
Current MDD
Atypical 26.8 (4.1) 1.77 (0.71 to 2.82)e 4.3 (7.7) 2.86 (1.19 to 4.53)f 3.03 (1.35 to 4.71)f 3.19 (1.50 to 4.88)f
Melancholic 25.4 (5.2) 0.16 (−0.83 to 1.15) 3.6 (7.1) 0.51 (−1.05 to 2.07) 0.53 (−1.04 to 2.10) 0.91 (−0.70 to 2.52)
Combined 26.3 (4.2) 1.41 (0.11 to 2.72)g 2.0 (8.5) 1.18 (−0.87 to 3.22) 1.46 (−0.59 to 3.50) 2.07 (−0.03 to 4.18)
Unspecified 25.1 (4.5) 0.02 (−0.73 to 0.77) 2.5 (7.0) 0.28 (−0.90 to 1.46) 0.41 (−0.78 to 1.60) 0.43 (−0.78 to 1.63)
Remitted MDD
Atypical 26.4 (5.2) 1.14 (0.50 to 1.78)f 3.2 (8.2) 1.12 (0.12 to 2.12)g 1.28 (0.28 to 2.29)g 1.18 (0.16 to 2.20)g
Melancholic 24.8 (4.8) −0.31 (−0.75 to 0.13) 4.0 (7.7) 1.20 (0.50 to 1.89)f 1.36 (0.65 to 2.07)f 1.43 (0.71 to 2.16)f
Combined 25.1 (3.9) 0.13 (−0.60 to 0.86) 2.1 (6.5) 0.16 (−0.98 to 1.31) 0.34 (−0.82 to 1.50) 0.49 (−0.68 to 1.66)
Unspecified 24.8 (4.1) −0.23 (−0.59 to 0.13) 2.6 (6.7) 0.14 (−0.42 to 0.70) 0.17 (−0.39 to 0.74) 0.23 (−0.34 to 0.80)
No MDD 25.5 (4.2) 0 [Reference] 2.2 (6.2) 0 [Reference] 0 [Reference] 0 [Reference]
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); MDD, major depressive disorder.
a Robust regression adjusted for age and sex.
bModel 1: robust regression adjusted for age, sex, socioeconomic status,
ethnicity, living alone, and length of follow-up.
c Model 2: model 1 and adjusted for physical activity, smoking habit, alcohol use,
drug dependence, anxiety disorders, antidepressant use, and
weight-increasing drug use.
dModel 3: model 2 and adjusted for the presence of major depressive episode
during follow-up.
e P < .01.
f P < .001.
g P < .05.
Table 3. Obesity at Baseline and Incidence of Obesity During Follow-up by Depression Status at Baseline Incidence of Obesity During Follow-up
According to Depression Status at Baseline
Depression Status
Obesity at Baseline(n = 3054) Incidence of Obesity During Follow-up
% OR (95% CI)a %
OR (95% CI)
Model 1(n = 2674)b Model 2(n = 2674)c Model 3(n = 2580)d
Current MDD
Atypical 14.6 1.23 (0.54-2.79) 17.1 3.58 (1.25-10.25)e 3.66 (1.23-10.95)e 3.75 (1.24-11.35)e
Melancholic 16.4 1.49 (0.71-3.11) 8.7 2.53 (0.60-10.61) 2.80 (0.67-11.74) 3.20 (0.75-13.64)
Combined 19.4 1.73 (0.69-4.32) 4.0 0.63 (0.07-5.67) 0.80 (0.09-7.04) 0.78 (0.09-7.05)
Unspecified 13.4 1.16 (0.63-2.13) 1.2 0.19 (0.02-1.55) 0.18 (0.02-1.47) 0.18 (0.02-1.50)
Remitted MDD
Atypical 20.0 0.69 (0.34-1.39) 8.9 1.53 (0.65-3.58) 1.73 (0.72-4.15) 1.88 (0.77-4.55)
Melancholic 10.5 1.98 (1.26-3.10)f 5.9 1.82 (0.94-3.55) 2.03 (1.03-4.02)e 2.11 (1.04-4.29)e
Combined 8.7 0.86 (0.58-1.27) 5.3 0.98 (0.32-3.07) 0.99 (0.32-3.07) 1.06 (0.34-3.32)
Unspecified 9.4 0.75 (0.54-1.04) 4.0 0.93 (0.51-1.67) 0.92 (0.50-1.67) 1.04 (0.57-1.92)
No MDD 13.0 1 [Reference] 5.1 1 [Reference] 1 [Reference] 1 [Reference]
Abbreviations: MDD, major depressive disorder; OR, odds ratio.
a Adjusted for age and sex.
bModel 1: logistic regression adjusted for age, sex, socioeconomic status,
ethnicity, baseline bodymass index, and length of follow-up.
c Model 2: model 1 and adjusted for physical activity, smoking habit, alcohol use,
substance dependence, living alone, anxiety disorders, antidepressant use,
and weight-increasing drug use.
dModel 3: model 2 and adjusted for presence of major depressive episode
during follow-up.
e P < .05.
f P < .01.
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Discussion
To our knowledge, the present study is the first to assess the
prospective associations between subtypes of MDD and the
subsequentchanges inadiposity in thegeneralpopulation.The
most salient findings were that (1) MDD with atypical fea-
tures is prospectively associated over a 5.5-year periodwith a
higher increase in adiposity in termsofBMI, incidenceof obe-
sity, andwaist circumference in both sexes aswell as fatmass
inmen. (2) Thehigher increaseof adiposity in individualswith
MDDwith atypical features is not explained by potential con-
founders including sociodemographic and lifestyle character-
istics, comorbid mental disorders, antidepressant medica-
tion, or other potentiallyweight-increasingmedications. And
(3) the elevated BMI increase in individuals with MDD with
atypical features is not a temporary phenomenon but per-
sists after the remission of the depressive episode and is not
attributable to new episodes.
The results of the present study should be considered in
the context of several limitations. First, the interval of ap-
proximately 1 year between the physical and the psychiatric
baseline evaluations entailed the risk for misclassifying cur-
rent episodes at thephysical baseline visit as remitteddepres-
sive episodes, which could have led to an overestimation of
the effect of remitted episodes on adiposity. Second, in 19%
ofparticipantswho refused thediagnostic interviewat the fol-
low-upvisit, theoccurrenceof adepressiveepisodeduring the
follow-up period needed to be determined using a depres-
sion scale rather thanadiagnostic interview.However, it is un-
likely that this limitation introduced a differential bias be-
cause participation at the interview did not differ across
diagnostic groups. Third, participants and nonparticipants at
the physical follow-up differed with respect to sociodemo-
graphic and behavioral characteristics, suggesting that indi-
viduals with a less healthy lifestyle were less likely to partici-
pate. Nonetheless, because only 13% of the initial sample did
not participate at the follow-up, it is unlikely that nonpartici-
pation introduced a substantial bias. Fourth, the data of the
present studywere based on anurban sample in Switzerland.
However, although the particular features of the sample are
likely to affect the prevalence estimates of diseases, it is less
likely that theysignificantly affect theassessedprospectiveas-
sociations between depression subtypes and adiposity. Fifth,
ourassessmentofphysical activityonlypartially reflecteddaily
activity and energy expenditure.
Theobservedstrongassociationbetween theatypical sub-
type of MDD and an increased BMI and waist circumference
confirms findings frompreviouscross-sectional research16,17,19
and is compatiblewith the results of a longitudinal studywith
multiple assessments between ages 20 and 40 years.18 As the
association between MDD and adiposity was almost exclu-
sively restricted toMDDwith atypical features in our study, it
is not surprising that the ORs of developing obesity for indi-
vidualswith this subtype (OR, 2.41)wasmuchhigher than that
of the association between the overall diagnosis of depres-
sion and obesity according to a recentmeta-analysis of longi-
tudinal studies (OR, 1.59).12 The discrepant results from pre-
vious studies, which did not assess specific MDD subtypes,
couldbeattributable tovariance in theproportionof theatypi-
cal subtype. This is probably also true for the inconsistent re-
sults of previous research regarding waist circumference. In-
deed, previous cross-sectional studies,whichdidnot subtype
depression, yielded 2 positive32,33 and 2 negative34,35 find-
ings. In addition, 1 prospective study based on a 5-year fol-
low-updocumentedapositiveassociationbetweencurrentde-
Table 4.Waist Circumference at Baseline andWaist Circumference Change During Follow-up by Depression at Baseline
Depression Status
Waist at Baseline, cm(n = 3054) Waist Change, % of the Baseline Value
Mean (SD) β (95% CI)a % (SD)
β (95% CI)
Model 1(n = 2988)b Model 2(n = 2988)c Model 3(n = 2883)d
Current MDD
Atypical 89.8 (11.8) 4.52 (1.53 to 7.51)e 6.8 (8.2) 2.31 (0.14 to 4.49)f 2.39 (0.20 to 4.58)f 2.44 (0.21 to 4.66)f
Melancholic 85.5 (14.6) 0.42 (−2.38 to 3.23) 5.4 (8.5) 0.55 (−1.46 to 2.57) 0.42 (−1.61 to 2.46) 0.51 (−1.59 to 2.61)
Combined 87.8 (10.6) 3.27 (−0.44 to 6.97) 4.2 (9.1) −0.43 (−3.09 to 2.23) −0.32 (−2.99 to 2.35) 0.12 (−2.64 to 2.89)
Unspecified 87.1 (13.0) 0.41 (−1.73 to 2.54) 5.5 (9.3) 1.09 (−0.45 to 2.63) 1.18 (−0.38 to 2.73) 1.04 (−0.55 to 2.64)
Remitted MDD
Atypical 88.7 (14.5) 3.52 (1.71 to 5.33)g 5.5 (9.1) 0.9 (−0.42 to 2.21) 1.01 (−0.31 to 2.34) 0.86 (−0.49 to 2.21)
Melancholic 85.1 (13.9) −0.64 (−1.89 to 0.61) 6.1 (9.9) 0.75 (−0.16 to 1.66) 0.81 (−0.12 to 1.74) 0.92 (−0.03 to 1.87)
Combined 85.6 (12.2) 0.65 (−1.42 to 2.72) 5.2 (9.2) −0.34 (−1.83 to 1.15) −0.31 (−1.82 to 1.20) −0.14 (−1.67 to 1.40)
Unspecified 85.4 (12.2) −0.74 (−1.75 to 0.27) 4.6 (8.3) −0.03 (−0.77 to 0.70) −0.09 (−0.83 to 0.65) −0.12 (−0.88 to 0.64)
No MDD 88.8 (12.9) 0 [Reference] 4.0 (7.6) 0 [Reference] 0 [Reference] 0 [Reference]
Abbreviation: MDD, major depressive disorder.
a Robust regression adjusted for age.
bModel 1: robust regression adjusted for age, sex, socioeconomic status,
ethnicity, living alone, and length of follow-up.
c Model 2: model 1 and adjusted for physical activity, smoking habit, alcohol use,
drug dependence, anxiety disorders, antidepressant use, and
weight-increasing drug use.
dModel 3: model 2 and adjusted for presence of major depressive episode
during follow-up.
e P < .01.
f P < .05.
g P < .001.
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pression and visceral fat increase but not with waist
circumference increase.36 The finding of a stronger associa-
tionof theatypicalMDDsubtypewithadiposity incurrent than
in remitted depressed participants in our study was attribut-
able to the higher degree of severity of current disorders. In-
deed, individuals whowere depressed at baseline weremore
likely to experienced long-lasting or highly recurrent depres-
sive episodes, whichwas reflected by the significantly longer
time they had spent in episodes than participantswith remit-
ted depression.
Interestingly, participants with remittedmelancholic de-
pression, who typically have decreased appetite during de-
pressive episodes, also gained more weight and had a higher
incidence of obesity during the follow-up period than those
who had never been depressed. However, these participants
did not reveal a higher BMI or a higher prevalence of obesity
at the follow-up than thosewho had never been depressed as
their lowbaselinemeasures aligned themselves to thoseof in-
dividuals who had never been depressed across time. The
weight gain of these participants likely reflected the compen-
sationof theweight loss that occurredduring thepreviousde-
pressive episode.
Conclusions
The present study provides additional insight into the com-
plex relationship between atypical depression and adiposity
by demonstrating that the high comorbidity between this de-
pression subtype and obesity is not simply attributable to the
occurrence of atypical depressive symptoms in already obese
individuals, but to a strong prospective association between
the atypical MDD subtype and adiposity. Moreover, this find-
ing strongly advocates the subtypingof theheterogeneousde-
pression diagnosis in future research.37 As suggested by pre-
vious research, specific depression subtypes are likely
associatedwithdifferent biological correlates andwithdiffer-
ential pathways to cardiovascular risk.37 Although it is plau-
Table 5. FatMass at Baseline and FatMass Change During Follow-up by Depression Status at Baseline
Depression Status
Body Fat Mass at Baseline, % Fat Mass Change, % of the Baseline Value
Mean (SD) β (95% CI)a % (SD)
β (95% CI)
Model 1b Model 2c Model 3d
Women, No. 1604 1324 1324 1281
Current MDD
Atypical 36.8 (7.8) 3.58 (1.10 to 6.07)e 11.0 (17.3) 1.05 (−5.44 to 7.53) 0.52 (−6.03 to 7.06) 0.72 (−6.06 to 7.50)
Melancholic 33.6 (8.1) 1.30 (−0.94 to 3.53) 9.3 (23.1) −3.91 (−9.49 to 1.67) −3.49 (−9.15 to 2.17) −2.84 (−8.76 to 3.08)
Combined 35.2 (7.8) 2.69 (−0.22 to 5.60) 11.9 (27.3) 4.26 (−3.19 to 11.71) 4.72 (−2.78 to 12.22) 4.46 (−3.35 to 12.28)
Unspecified 32.2 (7.0) 0.41 (−1.55 to 2.37) 7.3 (17.6) −0.91 (−6.00 to 4.18) 0.14 (−5.01 to 5.29) 0.73 (−4.62 to 6.09)
Remitted MDD
Atypical 34.9 (8.2) 2.45 (0.99 to 3.92)e 6.0 (20.1) −0.96 (−4.58 to 2.65) −0.63 (−4.27 to 3.02) −0.45 (−4.18 to 3.28)
Melancholic 32.1 (7.9) −0.31 (−1.38 to 0.76) 12.2 (26.2) 0.56 (−2.06 to 3.19) 0.87 (−1.80 to 3.54) 0.93 (−1.83 to 3.70)
Combined 33.5 (7.8) 1.12 (−0.58 to 2.82) 15.4 (72.6) −0.68 (−4.93 to 3.57) −0.6 (−4.94 to 3.73) 0.01 (−4.46 to 4.49)
Unspecified 32.5 (7.9) −0.18 (−1.08 to 0.73) 12.6 (51.8) −1.1 (−3.37 to 1.18) −1.17 (−3.46 to 1.13) −0.87 (−3.24 to 1.49)
No MDD 32.9 (7.9) 0 [Reference] 12.6 (41.6) 0 [Reference] 0 [Reference] 0 [Reference]
Men, No. 1423 1221 1221 1178
Current MDD
Atypical 23.5 (6.0) 0.47 (−1.98 to 2.93) 30.7 (36.5) 15.87 (4.45 to 27.28)e 16.55 (5.06 to 28.04)e 16.36 (4.81 to 27.92)e
Melancholic 23.4 (6.3) 1.24 (−1.30 to 3.77) 18.2 (20.4) 5.85 (−4.64 to 16.33) 6.43 (−4.07 to 16.94) 8.06 (−2.99 to 19.11)
Combined 26.6 (7.0) 2.75 (−0.71 to 6.21) 2.7 (18.3) −6.11 (−20.34 to 8.11) −6.76 (−20.95 to 7.43) −9.23 (−24.74 to 6.29)
Unspecified 22.9 (5.8) 0.33 (−1.17 to 1.83) 12.4 (19.8) 2.43 (−3.72 to 8.57) 3.36 (−2.82 to 9.55) 2.61 (−3.74 to 8.97)
Remitted MDD
Atypical 23.6 (6.7) 1.66 (0.05 to 3.27)f 11.6 (22.2) 0.67 (−5.82 to 7.15) 2.02 (−4.64 to 8.69) 1.97 (−4.85 to 8.78)
Melancholic 22.3 (6.0) −0.24 (−1.25 to 0.77) 16.6 (27.3) 3.15 (−1.07 to 7.38) 4.11 (−0.20 to 8.41) 3.28 (−1.21 to 7.76)
Combined 22.2 (4.6) 0.06 (−1.69 to 1.81) 8.5 (24.2) −0.33 (−7.53 to 6.87) 0.40 (−6.90 to 7.70) 0.01 (−7.37 to 7.39)
Unspecified 21.9 (5.1) −0.34 (−1.09 to 0.40) 12.4 (23.3) 0.84 (−2.27 to 3.95) 1.07 (−2.06 to 4.21) 0.90 (−2.32 to 4.13)
No MDD 22.8 (5.7) 0 [Reference] 10.5 (23.0) 0 [Reference] 0 [Reference] 0 [Reference]
Abbreviation: MDD, major depressive disorder.
a Robust regression adjusted for age.
bModel 1: robust regression adjusted for age, sex, socioeconomic status,
ethnicity, living alone, and length of follow-up.
c Model 2: model 1 and adjusted for physical activity, smoking habit, alcohol use,
drug dependence, anxiety disorders, antidepressant use, and
weight-increasing drug use.
dModel 3: model 2 and adjusted for the presence of major depressive episode
during follow-up.
e P < .01.
f P < .05.
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sible that increased appetite during depressive episodeswith
atypical features can lead to temporaryweight gain, our find-
ing of persistently elevatedBMI increase after a follow-uppe-
riod of more than 5 years, even in individuals with remitted
episodes, supports a potential obesity-related pathway from
atypical depression to CVD and other chronic diseases re-
lated to obesity. Mechanisms that could link depression and
obesity include adipokine, pro-inflammatory dysregulation,
alterations in the hypothalamic-pituitary-adrenal axis,38,39
weight-increasing effects of psychotropic medication, life-
style factors (poornutritionandphysical inactivity40), andpsy-
chological factors such as emotional eating and beliefs about
one’s inability to maintain physical activity behaviors in de-
pressed individuals.41 Other research also suggests thepoten-
tial involvementofgeneticdeterminants, suchas theFTOgene,
which has been shown to selectively favor weight gain in de-
pressed individuals.42 This gene could also be associatedwith
the atypical depression subtype.43 Another study supports a
specific association between the atypical depression subtype
andelevated inflammatorymarkers,which arewell known to
be associated with obesity, whereas hypercortisolemia was
linked to the melancholic subtype.37 Our results do not sup-
port a significant role ofmedicationorphysical exercise in the
prospective associationbetween atypical depression and adi-
posity, whereas the role of the hypothalamic-pituitary-
adrenal axis, adipokines, and inflammatory processes in this
association still needs to be determined in longitudinal re-
search.
For the clinician, the atypical subtype deserves particu-
lar attention because this subtype is a strong predictor of adi-
posity. Accordingly, the screening of atypical features and, in
particular, increased appetite in individuals with depression
is crucial. The prescription of appetite-stimulating medica-
tion should be avoided in these patients and dietary mea-
suresduringdepressiveepisodeswithatypical features are ad-
vocated.Clinical studiesneed todetermine towhatdegree the
timely andappropriate treatment of depressive episodeswith
atypical features can prevent an increase of adiposity during
andafter suchepisodes and thereby reduce the long-term risk
for CVD and other chronic diseases related to obesity.
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